US2014005122A1PendingUtilityA1
Gemcitabine combination therapy
Est. expiryApr 24, 2026(expired)· nominal 20-yr term from priority
A61K 38/12A61P 35/00A61K 38/15A61K 45/06A61K 31/7068
55
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides compositions and methods for the treatment of cell proliferative disorders using at least one DAC inhibitor and gemcitabine.
Claims
exact text as granted — not AI-modified1 . A method comprising steps of:
administering to a subject suffering from or susceptible to a cell proliferative disorder, combination therapy of a DAC inhibitor and gemcitabine.
2 . The method of claim 1 wherein the cell proliferative disorder involves a tumor.
3 . The method of claim 2 , wherein the tumor is a Ras-expressing tumor.
4 . The method of claim 2 , wherein the tumor is a pancreatic tumor.
5 . The method of claim 1 , wherein the DAC inhibitor is romidepsin.
6 . The method of claim 1 further comprising administering electrolyte supplementation.
7 . The method of claim 1 , wherein the cell proliferative disorder is cutaneous T-cell lymphoma.
8 . The method of claim 1 , wherein the cell proliferative disorder is peripheral T-cell lymphoma.
9 . The method of claim 1 , wherein the cell proliferative disorder is a hematological malignancy.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.